22 June 2020>: Clinical Research
Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade
Jingjing Chen 12ACE , Shao Liu 1ADE , Hui Xu 23AF* , Wei Wang 3BC , Yanyun Xie 3B , Wenbin Tang 3B , Qiongjing Yuan 3B , Li Zheng 4D , Lizhen Lin 35F , Shuangshuang Fu 6F , Jinmei Shen 7CDOI: 10.12659/MSM.922839
Med Sci Monit 2020; 26:e922839
Table 3 Multivariate Cox regression analysis for the effect of RASB on the primary outcome of IgAN patients only with persistent hematuria initially.
Models | All (n=110) | P | Patients without hypertension (n=99) | P |
---|---|---|---|---|
HR (95% CI) | HR (95% CI) | |||
Model 1* | ||||
With RASB | 0.34 (0.16–0.75) | 0.01 | 0.23 (0.09–0.59) | 0.002 |
Without RASB | Reference | – | – | – |
Model 2** | ||||
With RASB | 0.28 (0.12–0.65) | 0.003 | 0.21 (0.08–0.55) | 0.002 |
Without RASB | Reference | – | – | – |
Model 3*** | ||||
With RASB | 0.22 (0.09–0.53) | 0.001 | 0.17 (0.06–0.46) | 0.001 |
Without RASB | Reference | – | – | – |
* Adjusted by gender and age; ** adjusted by gender, age, hypertension, hyperuricemia, initial eGFR, duration from initial diagnosis to start of therapy and initial hematuria; *** Model 2+Oxford classification factors (M, E, S, T and C). RASB – renin–angiotensin system blockers; HR – hazard ratio; CI – confidence interval. |